Home > Compound List > Product Information
Teniposide_Molecular_structure_CAS_29767-20-2)
Click picture or here to close

Teniposide

Catalog No. DB00444 Name DrugBank
CAS Number 29767-20-2 Website http://www.ualberta.ca/
M. F. C32H32O13S Telephone (780) 492-3111
M. W. 656.65368 Fax (780) 492-1071
Purity Email david.wishart@ualberta.ca
Storage Chembase ID: 327

SYNONYMS

IUPAC name
(10R,11R,15R,16S)-16-{[(4aR,6R,7R,8R,8aS)-7,8-dihydroxy-2-(thiophen-2-yl)-hexahydro-2H-pyrano[3,2-d][1,3]dioxin-6-yl]oxy}-10-(4-hydroxy-3,5-dimethoxyphenyl)-4,6,13-trioxatetracyclo[7.7.0.0^{3,7}.0^{11,15}]hexadeca-1(9),2,7-trien-12-one
IUPAC Traditional name
(10R,11R,15R,16S)-16-{[(4aR,6R,7R,8R,8aS)-7,8-dihydroxy-2-(thiophen-2-yl)-hexahydro-2H-pyrano[3,2-d][1,3]dioxin-6-yl]oxy}-10-(4-hydroxy-3,5-dimethoxyphenyl)-4,6,13-trioxatetracyclo[7.7.0.0^{3,7}.0^{11,15}]hexadeca-1(9),2,7-trien-12-one
Brand Name
Vee M-26
Vumon
Veham-Sandoz
Vehem
Synonyms
Teniposidum [INN-Latin]
Teniposido [INN-Spanish]

DATABASE IDS

CAS Number 29767-20-2
PubChem SID 46507536
PubChem CID 34698

PROPERTIES

Hydrophobicity(logP) 1.5

DETAILS

Description (English)
Item Information
Drug Groups approved
Description A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Teniposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent cells from entering into the mitotic phase of the cell cycle, and lead to cell death. Teniposide acts primarily in the G2 and S phases of the cycle. [PubChem]
Indication Teniposide is used for the treatment of refractory acute lymphoblastic leukaemia
Pharmacology Teniposide is a phase-specific cytotoxic drug, acting in the late S or early G 2 phase of the cell cycle, thus preventing cells from entering mitosis. Teniposide causes dose-dependent single- and double-stranded breaks in DNA and DNA: protein cross-links.
Affected Organisms
Humans and other mammals
Half Life 5 hours
Elimination From 4% to 12% of a dose is excreted in urine as parent drug. Fecal excretion of radioactivity within 72 hours after dosing accounted for 0% to 10% of the dose.
Clearance * 10.3 mL/min/m2
External Links
Wikipedia
RxList
Drugs.com

REFERENCES